Latest Information Update: 01 Jul 2003
At a glance
- Originator Ebewe
- Class Benzofurans; Class III antiarrhythmics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
- 09 Jul 1998 New profile
- 09 Jul 1998 Preclinical development for Arrhythmias in Austria (Unknown route)